As climate pressure intensifies, managing high solar radiation is becoming a critical challenge for growers worldwide. ☀️🌱 @RovensaNext is proud to launch Luxyva® in Mexico, a next-generation biosolution designed to help crops maintain photosynthetic efficiency, physiological stability and productivity under high-radiation stress. By supporting the plant’s own regulatory processes, Luxyva® helps crops sustain energy balance and biomass accumulation during peak irradiation periods, translating physiological protection into measurable agronomic performance. Field trials under high-radiation conditions demonstrated: ✔️ 45–50% more fruits per plant ✔️ Up to 70% higher yield per plant in tomato crops Developed to support a wide range of crops and production systems, Luxyva® reinforces our commitment to #BiosolutionizeAgriculture through science-based solutions that help growers build resilience and performance in increasingly challenging climatic conditions. Read the full press release below. 👇 rovensanext.com/en/news/pres… Rovensa Next México #RovensaNext #Luxyva #Biostimulants #Biosolutions #SustainableAgriculture #ClimateResilience #CropPerformance #Agriculture #Innovation #PlantHealth

🥬 Want to grow more with less? 💪 #GAXY® helps vegetable crops reach their full potential with improved vigour, stress tolerance & consistent growth. An ultra-concentrated biosolution built for performance. 🥒 Grow more with less 👉 bit.ly/UPL_GAXY #UPLLtd #OpenAg

UPL Corp Brazil proudly presents NPP biosolution Kasumin®—the first and only systemic biofungicide registered in Brazil to tackle the root cause of crop diseases: mollicutes, the pathogens behind the damage. bit.ly/4sHL8Yc #uplcorp

Mark your calendars: $EXOZ investor update: 4Q full year 2025 - on - Tuesday, March 31, 2026 at 5:30 PM Eastern Time. CEO of @eXoZymes, Michael @Heltzen, will lead the call and will be joined by select members of the management team to review recent developments, ongoing initiatives, anticipated milestones, as well as host a question-and-answer period. You can pre-register for the webinar HERE: na2.hubs.ly/H04vNGP0 #enzymes #exozymes #nutraceuticals #cellfree #exozyme #biosolution #biomanufacturing #enzyme

At Rovensa Next, collaboration is our engine for innovation. Working closely with our technical leaders in Brazil, we continue to strengthen our #BiosolutionizeAgriculture campaign, delivering integrated biosolutions based on our product portfolio together with enabling technologies and agricultural practices to meet every crop need and help farmers grow more sustainably and profitably. Led by our Director of Global Portfolio of #Bionutrition, Camilo Chacon Guerrero, and Victor Sonzogno, Head of Brazil, and with the participation of Portfolio teams, R&D, Marketing and Sales leaders, the meeting focused on building biosolution‑based programs for each crop and each need, ensuring growers receive: 🌱 Technical value 💡 Solid agronomic knowledge 💧 Integrated, field‑ready biosolutions 📈 Maximum profitability and long‑term sustainability Working closely with our technical leaders in Brazil, we continue to strengthen our #BiosolutionizeAgriculture campaign, delivering biosolutions that meet every crop need and help farmers grow more sustainably and profitably. Together, we move one step further in shaping the future of agriculture. ➡️ @RovensaNextBr #RovensaNext #CropStrategies #SustainableAgriculture #AgInnovation #AgricultureTransformation #CropSolutions #PlantNutrition

What if every farming challenge had a biosolution? At @RovensaNext, we share insights and #biosolutions that boost crop performance while maximizing #sustainability. 👉 Follow us to discover how we’re transforming agriculture

_ @eXoZymes (Nasdaq: EXOZ) announced the achievement of a 100-fold scale-up of its N-trans-caffeoyltyramine (NCT) production process, demonstrating over 99% conversion from feedstock to product using its proprietary exozyme-based, cell-free biomanufacturing platform. eXoZymes Inc. is a @b2idigital Featured Company. See their full profile at b2idigital.com/exozymes-1. The announcement validates the scalability of eXoZymes’ cell-free enzyme technology, proving that complex biocatalytic reactions can maintain exceptional efficiency at industrial volumes. The scaled production was executed under partner-operated conditions by Cayman Chemical using standardized protocols, demonstrating that the exozyme technology can be successfully transferred to and operated by manufacturing partners. This milestone also demonstrates that enzyme-driven systems freed from cellular constraints can overcome fundamental limitations that have historically hampered commercial biomanufacturing. Several important competitive advantages were demonstrated by the announced breakthrough: • 100× Scale-Up Success: The reaction scaled from laboratory to industrial volumes while maintaining performance, proving linear scalability of the exozyme platform • Near-Perfect Efficiency: Over 99% conversion of feedstock to product achieved at scale, matching or exceeding small-scale conversion levels • Partner Validation: Production executed by Cayman Chemical, confirming process transferability • Cell-Free Advantage: Removing cellular constraints enables reliable, scalable production of molecules previously limited by traditional biomanufacturing Michael Heltzen, CEO of eXoZymes, commented, “Scaling a complex biocatalytic reaction by 100× while sustaining high feedstock conversion strengthens our belief that exozymes will form the foundation of the next generation of biomanufacturing. We’re very enthusiastic about this progress and see it as an important inflection point in demonstrating that cell-free, enzyme-driven systems can be engineered to operate reliably at scale. This truly opens the door to producing molecules that have historically been constrained by traditional manufacturing approaches.” Dr. Tyler Korman, CSO of eXoZymes, added further, “Achieving over 99% conversion at scale is a significant validation of our exozyme biosolution - both from a scientific as well as a commercial point of view.” Read the complete announcement: exozymes.com/blog/100x-scale… eXoZymes is led by an experienced management team including Michael Heltzen, CEO; Damien Perriman, CCO; Dr. Tyler Korman, CSO and Co-founder; Dr. Paul Opgenorth, VP of Development and Co-founder; Fouad Nawaz, VP of Finance; Dr. Zachary Karl, Ph.D., VP of Business Development; Lasse H. Görlitz, VP of Communications; and Amy Lunzer, Chief of Staff. To learn more about eXoZymes Inc., visit exozymes.com. For investor inquiries, visit exozymes.com/investor. Disclosure: David Shapiro, CEO of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted EXOZ stock, in line with B2i Digital’s practice of investing alongside its Featured Companies. This post is not intended to solicit the sale of EXOZ or any security, and it is not intended to offer any opinion on EXOZ as an investment. Conduct your own research and consult with your own professional advisors prior to making any investment decisions. See the complete disclosure in the Risks and Disclosures section of b2idigital.com/disclaimer.

🌱 Biosolutionize Agriculture in action across Europe! Rovensa Next continues expanding its biosolutions portfolio with two high-performance tools for sustainable crop protection. Orocide® Plus🍊, the first orange-oil-based biosolution authorized in France for late blight (Phytophthora infestans) in potatoes. 🔹 Powered by Orowet® technology to enhance coverage, spread, and contact activity for stronger preventive and curative efficacy. 🔹 Also authorized for aphid control in cereals. Tulga Spinex, spinosad-based bioinsecticide, certified for organic use. 🔹 Over 90% efficacy in trials against Tuta absoluta, Lobesia botrana, and Frankliniella occidentalis. 🔹 Fast knockdown effect, pollinator-safe, and IPM-compatible. Driving sustainable, effective, and accessible biocontrol across Europe. 🌿 ➡️ For more information, read the full press release here: rovensanext.com/en/news/pres… #RovensaNext #Biosolutions #BiosolutionizeAgriculture #OrocidePlus #OrowetTechnology #TulgaSpinex #Biocontrol #SustainableAgriculture #Innovation

💡Biosolutionize Agriculture, our science-back awareness campaign takes one step forward! This time, it starred in a session at the Italy Executive Program in Agribusiness Technical-Commercial and Marketing. Hosted by SMEA – Alta Scuola di Management ed Economia Agro-alimentare at Università Cattolica del Sacro Cuore, the program empowers future leaders of the Agribusiness with strategic and managerial skills. We are proud that our CCO, Riccardo Vanelli, delivered a keynote lecture on Rovensa Next and how Bioslutionize Agriculture addresses farmers’ challenges through integrated biosolution strategies, driving sustainability, resilience, and growth in agribusiness. Knowledge innovation = a stronger, more sustainable future for agriculture. @Unicatt #Agribusiness #SustainableAgriculture #Innovation #FoodSystem #Leadership #LetsGrowGreener

_ @eXoZymes (Nasdaq: EXOZ) Inc. (NASDAQ: EXOZ) announced its Q3 operational update for the fiscal quarter ended October 31, 2025. During the quarter, eXoZymes continued to advance multiple development and commercialization pathways across its platform. The company highlighted progress within its purpose-built NCTx subsidiary, ongoing development of its santalene biosolution for sustainable fragrance production, and continued work on its non-intoxicating cannabinoid program. The company also noted organizational expansion and strengthened capabilities across R&D, operations, and scientific leadership. Notable developments during the quarter included: • NCTx advanced its exploratory analog program, which remains contingent on further development, validation, regulatory processes, and commercialization outcomes • Continued parallel development of santalene and non-intoxicating cannabinoid assets • Expanded R&D capabilities and leadership team to accelerate product development • The company ended Q2 2025 with $5.1 million in cash and cash equivalents, supporting operations into the beginning of Q2 2026 • Appointment of Amy Lunzer as Chief of Staff and Dr. Tyler Korman, co-founder of eXoZymes and cell-free biomanufacturing specialist, as Chief Scientific Officer CEO Michael Heltzen commented: “Since our last quarterly update, we have worked diligently on maturing our core assets – both scientifically as well as commercially – including what the ideal go-to-market strategies are for each of these. We look forward to sharing these details with our investors on the call today.” eXoZymes is a Monrovia, California-based biotechnology company pioneering cell-free biomanufacturing through AI-engineered enzymes that transform sustainable feedstock into nutraceuticals, medicines, and essential chemicals. The company’s proprietary exozyme platform offers a scalable, eco-friendly alternative to traditional petrochemical processes, with technology validated through publications in Nature Communications and Nature Chemical Biology. Recently demonstrating gram-scale production of NCT with over 99% purity in just five months, eXoZymes focuses on high-value products including active pharmaceutical ingredients, nutraceuticals, and sustainable aviation fuel. eXoZymes is led by an experienced management team including Michael Heltzen, CEO; Damien Perriman, CCO; Dr. Tyler Korman, CSO and Co-founder; Dr. Paul Opgenorth, VP of Development and Co-founder; Fouad Nawaz, VP of Finance; Dr. Zachary Karl, Ph.D., VP of Business Development; Lasse H. Görlitz VP of Communications; and Amy Lunzer, Chief of Staff.

Our CEO, Michael Heltzen (@heltzen), will present at the Spartan Capital Securities’ (@SpartanCapSec) second annual investor conference on Monday! Heltzen states, "By using the ingenuity of biology, coupled with AI, and combining it with the scalability of chemical engineering – we have solved the scaling bottleneck of synthetic biology. Our first flagship product is a natural product compound called NCT, which is a small molecule that burns fat and creates energy and has multiple positive indications towards metabolic diseases and gut health – global markets totaling over 100 billion dollars, combined. I’m excited to detail this to investors at Spartan’ Capital’s investor conference next week!" Michael Heltzen will be presenting eXoZymes to investors on Monday, November 3, at 11:20-11:35 AM at Track 4 at the Marriott Marquis Hotel in New York City. Full story here: na2.hubs.ly/H01R6nf0 #synbio #enzymes #exozymes #nutraceuticals #cellfree #exozyme #biomanufacturing #biosolution #syntheticbiology #enzyme

Driving the cell-free revolution: @eXoZymes leaders join @TheBioMADE Leadership & Technical Committees. This underscores eXoZymes’ commitment to - and growing influence as a thought leader in - cell-free biomanufacturing. Chief Commercial Officer at eXoZymes, Damien Perriman (@Perriman), states, "Being elected to the BioMADE Leadership Council is both an honor and a responsibility. This is a pivotal moment where cell-free biomanufacturing is stepping into the national spotlight. At eXoZymes, we believe our technology will be instrumental in driving the shift toward faster, more scalable, and more resilient biomanufacturing. I look forward to working with fellow council members to shape priorities that unlock real-world impact across industries - from fuels to functional ingredients.” Co-founder and VP of Development, Dr. Paul Opgenorth (@popgenorth), states, “The Technical Committee is where the details of innovation become the standards that move an industry forward. I’m excited to play a role in defining a technical roadmap for developing and deploying cell-free enzyme pathways in the real world that can accelerate biosolution development cycles, remove the cell-based bottlenecks, and make a new generation of highly valuable natural product molecules commercially viable at scale.” Full story here: hubs.la/Q03LB2sg0 #enzyme #syntheticbiology #biomanufacturing #biosolution #exozyme #cellfree #exozymes #enzymes #synbio

Note Karen Esperson's corp that was founded as the IBIO123 trial commenced, is now Liable for dissolution, and Stu Greenberg severed ties with the trial and the BC Ostrich farm (he now gets his hair re-growth IgY's from an Arizona herd). Don't lose sight of the fact the Immune BioSolution trial had $4.5MM of private equity in addition to CSIF and Quebec Gov't cash. Are they looking to shore up a negative balance sheet on the non-Governmental portion of the trial? Esperson claimed to have injected all Hen's with IBIO123 precursor viruses in 2023, while concurrently harvesting Ostriches for human consumption. IMO this is a PHAC Timmy Tam screw up being swept under the rug using CFIA and the RCMP. 🤔 @Babylon_Beaver

@BRAINbiotech and @CorbionFood have reached agreement to collaborate in the development of novel bio-based antimicrobial compounds and its derivatives. Find the respective press release at t1p.de/pbgn7 #futurefood #foodindustry #biosolution

“Producing 4 grams of NCT at a purity higher than 99% is the kind of validation a novel platform like ours needs, to demonstrate the immense potential. Compared to extracting this from natural resources, which is the current way, you would need tens of kilograms of hemp seeds to produce the same quantity and then you’d have the headache of extracting it. That’s obviously neither an effective nor sustainable approach, which is why our exozyme biosolutions are the perfect way forward - both for NCT as well as other naturally sourced compounds.” - states co-founder and VP of Research at @eXoZymes, Dr. Tyler Korman (@tylerkorman] 📽️ Full story here: exozymes.com/blog/nct-breakt… 👉 Early access partnerships now open: exozymes.com/partners #exozymes #exozyme #Enzyme #Enzymes #Biomanufacturing #SyntheticBiology #SynBio #Nutraceutical #Nutraceuticals #Pharmaceuticals #Supplements #DietarySupplements #Prebiotics #FunctionalIngredients #Nutrition #NCT #NTransCaffeoyltyramine #DigestiveHealth #GutBarrierFunction #HealthyLiverFatMetabolism #MitochondrialActivity #Mitochondrial #IrritableBowelSyndrome #biosolution #biosolutions $EXOZ

🔬 Biomanufacturing breakthrough detailed: 4 grams of NCT produced at a 96% yield and with a purity higher than 99% 💥 Chief Commercial Officer at @eXoZymes, Damien @Perriman, states: "The beauty of leading with NCT as our first push to market, is that the compound has already been self-affirmed in the market as generally recognized as safe (GRAS) for functional foods. Additionally, it has multiple potential applications across different verticals in prebiotics, dietary supplements, and pharmaceuticals. We’re ramping up NCT production scale 100X over the next six months to both deliver samples to our partners as well as prepare for tech transfer to GMP pilot scale production next year. We are ready to start partner discussions for kilogram demand in 2026 and beyond that - ton scale.” 📽️ Full story here: exozymes.com/blog/nct-breakt… 👉 Early access partnerships now open: exozymes.com/partners #exozymes #exozyme #Enzyme #Enzymes #Biomanufacturing #SyntheticBiology #SynBio #Nutraceutical #Nutraceuticals #Pharmaceuticals #Supplements #DietarySupplements #Prebiotics #FunctionalIngredients #Nutrition #NCT #NTransCaffeoyltyramine #DigestiveHealth #GutBarrierFunction #HealthyLiverFatMetabolism #MitochondrialActivity #Mitochondrial #IrritableBowelSyndrome #biosolution #biosolutions $EXOZ

🚀 Biomanufacturing breakthrough: Using our AI-powered, cell-free exozyme platform, we’ve gone from proof-of-concept to lab-scale validation of NCT with 96% reaction yield and at a fraction of the normal R&D cost - in just 5 months! CEO of @eXoZymes Michael @Heltzen, states: “This biomanufacturing breakthrough of producing NCT is a massive accomplishment by our team and our exozyme platform! Not only can we produce NCT way more efficiently than any current methods, but we’ve also reached this milestone in record time – an ability to drive the development and initial validation at unprecedented speeds. This is the perfect showcase for the potential of our 'powered by eXoZymes' platform, which can be used to build biosolutions for 100s of different and valuable chemicals. Remember, NCT is just our first of more 'powered by eXoZymes' natural products, that can both be taken to market as nutraceuticals, or in optimized or analog versions that has a pharmaceutical potential.” 📽️ Full story here: hubs.la/Q03ykrf90 👉 Early access partnerships now open: hubs.la/Q03ykfMk0 #exozymes #exozyme #Enzyme #Enzymes #Biomanufacturing #SyntheticBiology #SynBio #Nutraceutical #Nutraceuticals #Pharmaceuticals #Supplements #DietarySupplements #Prebiotics #FunctionalIngredients #Nutrition #NCT #NTransCaffeoyltyramine #DigestiveHealth #GutBarrierFunction #HealthyLiverFatMetabolism #MitochondrialActivity #Mitochondrial #IrritableBowelSyndrome #biosolution #biosolutions $EXOZ

🚀 Biomanufacturing breakthrough: Using our AI-powered, cell-free exozyme platform, we’ve gone from concept to gram-scale NCT in only 5 months! Co-founder and VP of Development at eXoZymes, Dr. Paul Opgenorth (@popgenorth), states: "Going from the original proof-of-concept to lab scale validation, our goal was to make a first version of a biosolution that can produce at least one gram of NCT per batch, which we now have delivered on with an impressive 96% reaction yield. Not only does this biomanufacturing breakthrough prove the technical proficiency of our platform - but we have also accomplished this in only 5 months and with a limited budget. A timeline that’s unheard of in SynBio or anywhere, really.” This isn’t just a milestone for NCT - it’s a validation of our 'powered by eXoZymes' biosolution platform that can unlock 100s of valuable natural products. 📽️ Full story here: exozymes.com/blog/nct-breakt… 👉 Early access partnerships now open: exozymes.com/partners #exozymes #exozyme #Enzyme #Enzymes #Biomanufacturing #SyntheticBiology #SynBio #Nutraceutical #Nutraceuticals #Pharmaceuticals #Supplements #DietarySupplements #Prebiotics #FunctionalIngredients #Nutrition #NCT #NTransCaffeoyltyramine #DigestiveHealth #GutBarrierFunction #HealthyLiverFatMetabolism #MitochondrialActivity #Mitochondrial #IrritableBowelSyndrome #biosolution #biosolutions $EXOZ

Bioterror July4,Evidence: 1 WHO PandemicAgmt May 2 Nipah Virus Vax Approve 3 July4 important 4 Israel/Jewish History & US 4 Botulism cocktail Nipah allow in doc,Emergent Biosolution,Kennedy HHS give 62mil Botulism AntiToxin 5 Pandemic Seminar today Oxford whose Nipah Vax it is

Yesterday at @SynBioBeta, we launched NCTx - our new purpose-built subsidiary dedicated to unlocking the full potential of N-trans-caffeoyltyramine (NCT). A rare natural compound with powerful promise in liver health, gut integrity, and metabolic function. Chief Commercial Officer at @eXoZymes, Damien Perriman (@Perriman), states: "Launching NCTx, is a milestone in going from idea to demonstrated target – a breakthrough in speed for biomanufacturing innovation. Proof of concept was completed in 6 weeks and the subsidiary assembled in 12 weeks - a speed of development I have not seen before in synthetic biology. And it's not just a lucky one-off instance, as we have repeated the study 25 times to validate our proprietary exozyme biosolution to produce NCT. With this proof of concept in hand, we are well positioned to advance through scale-up and start providing samples for our future nutraceutical and pharmaceutical partners." $EXOZ #SynBio #synbiobeta25 #AI #biomanufacturing #LiverHealth #nutraceuticals #BiotechInnovation #MASLD #NAFLD #NCT #NCTx #FunctionalFood #PharmaTech #biotechnology #enzymes #exozymes